Observatorio de I+D+i UPM

Go Back | Technology Solutions

MEG-HERMES. Magnetoencephalography recordings analysis

More info

[MEG]Commercial_sheet_UPM_EN(Innovatech) PDF
 
Briefing

High Health oriented Technology  

Magnetoencephalography (MEG) is a noninvasive brain mapping technique used to measure the magnetic fields  produced by neuronal electrical activity. MEG study provides medical doctors with conclusive presurgical evaluation of patients with Epilepsy. MEG adds complementary information as the localization of the epileptogenic area and the seizure propagation. Competitive advantages/Main benefits: High temporal resolution and good spatial resolution locating epileptogenic seizure; Quick noninvasive and painless medical test.
The diagnosis is made with HERMES, a data analysis software, developed by the laboratory and with continuous improvement based on the Laboratory Experience and User Feedback. 5 years in operation; 3,000 cases resolved. HERMES is available to users worldwide for download and use: 24,000 visits in the last six months; 2,819 downloads

 
Technology Solution

Research on and applications of MEG data analysis improve medical resolution of up to 80% of unsolved cases through EEG or MRI.

Methodology of epileptogenic seizure location has been developed by the multidisciplinary group of the CCNL researchers (engineers, medical doctors, neurophysiologists, psychologists and neuropsychologists) with more than 15 years of experience and  analysis of 3.000 cases.

Epileptogenic seizure location is essential to lead a successful surgical treatment for surgical cases whilst in non-surgical cases, medical report based on MEG is considered as an Epilepsy diagnostic support.

Software Hermes development by Cognitive and Computational Neuroscience Lab: 21 Connectivity Measures. Continuous Improvement based on laboratory experience and feedback from users.

“HERMES - It has been operational for 5 Years. 3,000 cases resolved”

 
Market demands

  • There is a national requiring need of accessing to a conclusive diagnostic and presurgical evaluation technology in the following pathologies: Epilepsy; Brain tumors (functional mapping); Dementia and Cognitive impairment
  • Potential users are Medical Staff: Neurologists; Neurophysiologists; Surgeons.
  • Needs of developing personalized medicine through an improvement in data recording, processing and analysis. The group of researchers is focused on the customization of Data Analysis adjusting them to customer and specific project needs.
 
Market potential

  • More than 400.000 patients with Epilepsy in Spain, almost half of them are children [Info :Sociedad Española de Neurología- SEN]
  • 50 millions of people suffer from epilepsy in the world. 6 millions in Europe.
  • 80% of epileptic patients are wrongly diagnosed and are receiving inaccurate treatment. In Europe this figure is up to the 40%.
  • 70% of epileptic patients can benefit through efficient diagnosis and treatment.
 
Competitive advantages

SOFTWARE HERMES:

  • 21 Connectivity Measures compared to any other software (4-7  Connectivity Measures)
  • Acceptability: 24,000 visits in the last six months. / 2,819 downloads
  • Location Views / downloads: Europe / Middle East / Asia / Oceania / North America / South America
  • 20 Times Cited
  • Continuous Improvement based on laboratory experience and feedback from users. (4 future implementation of new synchronization algorithms)
  • It has been operational for 5 Years / 3,000 cases resolved

“CONCLUSIVE Clinical Test in patients with Epilepsy. Exclusive Technology in combination with a high qualified group at the Cognitive and Computational Neuroscience Laboratory at the Center for Biomedical Technology”

 
References

  • One of the three equipment in Spain; it has the Exclusivity Certificate in the Community of Madrid. It is the only MEG system in Spain used for Clinical Activity.  The CTB is autorithed as a Clinic Area
  • The Cognitive and Computational Neuroscience Laboratory is a multidisciplinar group (engineers, neurologists, neruphysiologists, psychologists, neuropsychiologists) with more than 15 years of experience.
  • More than 3.000 cases in 15 years back up the evidences achieved at the CCNL at the Center for Biomedical Technology.
  • Internationally recognized Center
 
Development stage

  • Concepto
  • Investigación
  • Prototipo-Lab
  • Prototipo Industrial
  • Producción
 
Contact

HERMES Contact

Francisco del Pozo; Fernando Maeztu; Mª Jesús Pioz

e: mariajesus.pioz@ctb.upm.es

http://www.ctb.upm.es/?page_id=165

UPM Contact

Innovation, Commercialization and Entrepreneurship Area

Centre of Support for Technological Innovation – UPM 

e: innovacion.tecnologica@upm.es

 
S2i 2019 Observatorio de investigación @ UPM con la colaboración del Consejo Social UPM
Cofinanciación del MINECO en el marco del Programa INNCIDE 2011 (OTR-2011-0236)
Cofinanciación del MINECO en el marco del Programa INNPACTO (IPT-020000-2010-22)